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n Bleeding in Acute
oronary Syndromes*
aul W. Armstrong, MD, Robert C. Welsh, MD
dmonton, Alberta, Canada
uman beings, who are almost unique in having the ability
o learn from the experience of others, are also remarkable
or their apparent disinclination to do so.
—Douglas Adams, Last Chance to See (1)
arge-scale registries continue to provide useful information
egarding the contemporary management of acute myocar-
ial infarction. Moreover, given the plethora of major
dvances in pharmacological therapy, coupled with the
ncreasing momentum toward early invasive study and
oronary intervention, they provide an instructive rear-
iew window into how the results of clinical trials are
mbraced (or not) by the medical community. Hence, in
his issue of JACC: Cardiovascular Interventions, the
bservations from the NCDR (National Cardiovascular
ata Registry) ACTION (Acute Coronary Treatment
nd Intervention Outcomes Network) Registry of Kada-
ia et al. (2) in over 100,000 patients studied between
anuary 2007 and June 2009 give us a fresh and informa-
ive look at the use of anticoagulants across the spectrum
See page 1166
f acute coronary syndrome (ACS) patients. Their data,
rovided herein, from this important cohort of whom
pproximately two-thirds were non–ST-segment elevation
yocardial infarction (NSTEMI), convincingly demon-
trate that the CRUSADE (Can Rapid risk stratification of
nstable angina patients Suppress ADverse outcomes with
arly implementation of the ACC/AHA guidelines) bleed-
ng risk score acquired from key baseline variables reliably
racks the occurrence of major bleeding in both NSTEMI
Editorials published in the JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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oehringer Ingelheim.nd ST-segment elevation myocardial infarction (STEMI)
atients (3).
The study also reveals several interesting and remarkable
aradoxes: 1) despite repeated demonstration of the supe-
iority of alternate anticoagulant regimens over conventional
nfractionated heparin, this venerable therapeutic standard
emains the most commonly used agent as represented in
wo-thirds of the STEMI and nearly one-half of the
STEMI patients; 2) despite the known bleeding hazards
f low molecular weight heparin in elderly patients (of
hom many were female) and those with diminished renal
unction, this agent proved to be the most common anti-
oagulant employed in this very same subset; 3) although
ithin patient “crossover” of anticoagulant therapies is
nown to be associated with excess bleeding, this pattern of
oint usage seems to persist, not only as it relates to
oncomitant unfractionated and low molecular weight hep-
rin but, interestingly, also with bivalirudin. However, the
upplementary data tables do not permit specification as to
hich additional anticoagulant was used. Finally, not sur-
risingly, the uptake of bivalirudin shows a steady rise in
oth STEMI and NSTEMI patients beginning in the third
uarter of 2007 (4–6). It is not surprising, however, that
here was concomitant use of glycoprotein IIb/IIIa platelet
nhibitors in nearly one-half of the STEMI patients and
ne-quarter of the NSTEMI cohort without supporting
vidence (7,8). Overall, major bleeding seems distressingly
ommon among this large cohort of patients averaging
pproximately 9% in the NSTEMI and 12% in the STEMI
roups with a remarkable 6-fold spread in incidence as
efined by the CRUSADE bleeding score derived from
aseline variables (3).
Although Kadakia et al. (2) assert that the bleeding they
ave characterized is “largely based on differences in baseline
haracteristics, comorbidities, and invasive treatment strat-
gies rather than specific anticoagulant regimens” we con-
ider this premise tentative. Further knowledge about the
iming of anticoagulant therapy commencement; its dose
nd duration; the frequency of medication errors; and how
he inevitable variety of dynamic changes and comorbidities,
uch as renal function unfolding after the index event,
ffected the management of this group of patients would
elp illuminate this issue (9). Moreover, the absence of
egistry data on the prior use of antiplatelet agents, such as
spirin and clopidogrel, as well as the timing of concomitant
ntiplatelet therapy (and its dose) are gaps in the current
eport that would also be expected to further inform on the
ccurrence of bleeding. Other key variables that are neces-
ary to provide more context include the vascular access site
or coronary intervention, the location of major bleeding,
nd how frequently blood transfusion was employed (4).
ndeed, without knowing the longer-term follow-up and
he context of clinical outcome data, the balance of benefit
nd risk of anticoagulant therapy are challenging to mea-
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1179ure. Whereas the rather high rates of bleeding in this
ohort are impressive, the fact that this study excluded
atients who were transferred between hospitals as well as
hose who went on to coronary bypass surgery suggests that
he true rate of major bleeding in the overall population is
ikely even higher (2).
Evidence-based guidelines encourage clinicians to calcu-
ate risk scores to facilitate clinical decisions regarding the
ntensity of pharmacological therapy and the need for and
iming of invasive investigation and revascularization in
CS (10,11). Our own experience suggests that, despite the
elative ease of calculating risk scores with handheld or
nline computer programs, there is limited use of risk scores
n daily clinical practice. The additional value of a bleeding
isk score to an “ischemic” risk score is debatable, because
here is substantial overlap in the variables used for both. To
emonstrate this we calculated—on a recent ACS patient in
ur coronary care unit—the GRACE (Global Registry of
cute Coronary Events) risk score (in-hospital death or
yocardial infarction 21%) and CRUSADE bleeding risk
core (in-hospital major bleeding 9.2%) (Fig. 1) (12). As
ill be evident, the same patient in whom an intensive
harmacological therapy and early aggressive invasive strat-
gy is recommended is also at the highest risk of bleeding.
herefore, the frontline clinician receives a dilemma-
25
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Figure 1. Baseline “Ischemia” Risk Assessment and Bleeding Risk
Baseline “ischemia” risk assessment (GRACE [Global Registry of Acute Coro-
nary Events]) and bleeding risk (CRUSADE [Can Rapid risk stratiﬁcation of
Unstable angina patients Suppress ADverse outcomes with Early implemen-
tation of the ACC/AHA guidelines]) were calculated on a recent non–ST-
segment elevation myocardial infarction (MI) patient (blue bar and line).
Estimates of the beneﬁt of implementing an intensive anticoagulation
regime combined with an early invasive strategy were calculated on the
basis of the high-risk population in the TIMACS (Timing of Intervention in
Acute Coronary Syndrome) study (orange bar and line) (12). Estimates of
the risk of implementing this regimen compared to a conservative pharma-
cological approach were calculated from the SYNERGY trial. The magnitude
of beneﬁt (green arrow) and risk of bleeding (red arrow) shift differen-
tially depending on individual baseline patient characteristics, evolution of
risk during hospital stay, anticoagulant strategy, and timing of invasive
assessment.olored message regarding “optimal” care. A single inte-
rated risk score that combines both efficacy and safety
eatures would enhance decision-making for the practicing
linician.
Notwithstanding these limitations, the authors have pro-
ided an important and strikingly sober reminder of the
isks of contemporary antithrombotic therapy in a popula-
ion receiving concomitant antiplatelet agents and com-
only undergoing invasive procedures. How promptly and
ow specifically feedback to individual contributing centers
nd practitioners is provided, given the likely but unknown
eterogeneity of bleeding events across the 360 U.S. hospi-
als participating in this large registry, will be critical in
chieving the desired quality improvement that such helpful
egistries are ultimately aimed at achieving. The recent
mergence of updated American College of Cardiology/
merican Heart Association performance measures in ACS
atients who emphasize oversight of excessive dosing of
nticoagulants and the implementation of a tracking system
f identifying dosing errors should prove helpful in this
espect (13).
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